{"nctId":"NCT00770562","briefTitle":"A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)","startDateStruct":{"date":"2005-07"},"conditions":["Idiopathic Thrombocytopenic Purpura"],"count":103,"armGroups":[{"label":"Dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dexamethasone"]},{"label":"Dexamethasone plus Rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab","Drug: Dexamethasone"]}],"interventions":[{"name":"rituximab","otherNames":["MabThera/Rituxan"]},{"name":"Dexamethasone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients \\>=18 years of age;\n* untreated ITP.\n\nExclusion Criteria:\n\n* ITP with relapse;\n* positive test result for HIV or hepatitis B or C;\n* active infection requiring systemic therapy;\n* malignancy within 3 years before study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Sustained Response","description":"Sustained response defined as a platelet count of greater than or equal to (≥) 50x10\\^9/L at 6 months (Week 24) after the initial treatment. Participants failing therapy before Month 6 (Week 24) and treated in other ways were considered failures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Initial Response","description":"Initial response was defined as an increase in platelet count of ≥50x10\\^9/L by Day 30 (Week 4) after the start of treatment in either treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Initial Complete Response","description":"Initial complete response was defined as an increase in platelet count of ≥100x10\\^9/L by Day 30 (Week 4) after the initiation of treatment in either treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Pyrexia","Headache","Cough","Abdominal pain upper","Asthenia"]}}}